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Minimally Invasive Surgery 				
for Skull Base Tumors
James J. Evans, MD1 and Marc R. Rosen, MD2
Department of Neurological Surgery and 2Department of Otolaryngology-Head and Neck
Surgery Thomas Jefferson University, Philadelphia, Pennsylvania

1

The Jefferson Center for Minimally Invasive Cranial Base Surgery and Endoscopic Neurosurgery
reflects three of the current evolutions in neurological surgery. The first of these is reflected in the
name of the Center itself. Surgical Procedures, Minimally Invasive, a Medline Subject Heading since
1998, is defined as:
Procedures that avoid use of open invasive surgery in favor of closed or local surgery. These
generally involve use of laparoscopic devices and remote-control manipulation of instruments
with indirect observation of the surgical field through an endoscope or similar device. With
the reduced trauma associated with minimally invasive surgery, long hospital stays may be
reduced with increased rates of short stay or day surgery.
Traditionally, cranial base tumors have been removed by making craniotomies or cranial base
ostomies, and possibly by removing facial bones. To access these areas, surgeons usually need to
make potentially disfiguring incisions in the face and scalp. Sometimes the morbidity from the
“open” cranial base approach alone could be significant, even with an uneventful removal of the
tumor.
At the Center, the endoscopic approaches are usually through the nose or nasal passages (Figure 1),
however transoral endoscopic approaches to the cranial base and cervical spine are also performed.
Because morbidity from the minimally invasive endoscopic approaches is so low, it becomes possible
to treat patients with tumors that were previously considered non-resectable or as having too poor a
prognosis for more invasive surgery. Even partial resection of such tumors can relieve pain, preserve
function, and permit earlier adjuvant radiation and chemotherapy.
James Evans, MD and Marc Rosen, MD, both faculty at Jefferson Medical College of Thomas Jefferson
University (Evans in Neurological Surgery, Rosen in Otolaryngology-Head and Neck Surgery), are
the Center’s co-directors. Their collaboration represents another evolution, the increasing interaction
between medical and surgical disciplines (Figure 2). Both specialties bring unique instruments,
surgical techniques, and clinical experience that have been merged to exponentially increase our
understanding and management of cranial base tumors and disorders. Treatment of these patients
in the Center also draws upon knowledge and resources from many other departments including
Radiology, Oncology, and Ophthalmology.
The third evolution is in the tracking of patient outcomes. Through the Center, we have developed a
specialized database for tracking patient demographics, neurological examinations, ENT parameters,
endocrine function, ophthalmologic evaluations, tumor control, morbidity, and outcomes. Data
collection is essential for confirmation of treatment efficacy and safety. Continual re-evaluation of
the treatment process and results can be critical when developing and validating new endoscopic
techniques. Also, the “Pay for Performance” movement is a recent addition to the reasons why
clinical organizations need to collect and store data that can be searched and cross-referenced. Data
at our Center is stored and retrieved using a Microsoft Access database application designed in-house
(Figures 3 and 4). With five years of accumulated data, the Center is now getting a clear view of what
it has achieved and what the next goals should be.

Table 1. Advantages of Endoscopic
Surgery over “Open” Surgery
Better preservation of function and
appearance
Lower morbidity rates
Shorter hospital stays
Greater resections of tumors
Facilitates re-operations
Permits earlier post-operative radiation and
chemotherapy
studies such as optical coherence tomography
not only document the extent of presenting
visual loss, but may be used as a predictor of
visual improvement with resection of the tumor
and decompression of the optic chiasm.
Another area of interest in our Center is the
extension of cranial base approaches to include
tumors involving the cervical spine. Figure 1
shows an endoscopic transnasal view of the
posterior pharyngeal wall and accompanying
intraoperative navigation images. We have
recently completed a morphometric study on
over 100 patients to determine the factors that
affect the extent of cervical spine access via an
endonasal surgical approach. These findings
have led to the development of new techniques
and instruments for endonasal cervical spine
surgery.
Endoscopic transnasal procedures continue to
benefit from technological developments such
as real-time intraoperative imaging (MRI, CT),
dedicated endoscopic surgical suites, and the
development of new materials and techniques
for cranial base repair. We are also exploring
the adaptation of surgical robotics systems to
augment the precise and delicate nature of these
endonasal surgical procedures.

Many of the Center’s patients present with pituitary tumors. Pituitary adenomas represent one of the
most common brain tumors and were the first type of tumor where endonasal endoscopic techniques
were used. Sixty percent of the patients seen by the Center for such tumors present with visual
deterioration. A recent study published by members of our Center has shown that ophthalmologic
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Clinical Guidelines Written by Residents
David W. Andrews, MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

“Variation” is an innocent word that that can represent many levels of frustration to the clinician. Variation among patients is the least of these;
the physician expects patients and their individual problems to be as diverse as the human race itself. Variation within a practice should be due
to matching the specific needs of the specific patient. Other variations can mean trouble if they represent differences in understanding of the
problem among clinicians and other allied health practitioners. These differences could be between institutions or even between shifts within
one institution.
The Tufts Health Care Institute (THCI) is a non-profit organization which provides educational tools for medical and surgical residents across
the US. One of these tools teaches clinical practice guidelines, defined by the Institute of Medicine as “systematically developed statements to
assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.”1. One of the authors of the Clinical
Guidelines module is David B. Nash, Professor of Health Policy here at Thomas Jefferson University.
The Jefferson Department of Neurological Surgery has been participating in the THCI program for the past few years, mentored by Dr. David W.
Andrews of the department. Because surgery and medicine have different emphases, Dr. Andrews has found that some of the THCI modules are
more appropriate than others for the neurosurgical residents, and that the Clinical Guidelines module in particular has generated both enthusiasm
and good results. A selection of the TJU neurosurgical resident-generated guidelines are presented here. These guidelines have not officially been
adopted by the department or by any institution that we know of, but show how clinical problems can be identified and solved.
References
1.

(Institute of Medicine, 1990, p. 38) Institute of Medicine. Field MJ, Lohr KN (eds.) Clinical Practice Guidelines: Directions for a New Program, page 38. Committee to Advise the Public Health
Service on

Acknowledgement
All graphics used are from commons.wikipedia.org under open licenses. The specific license of each graphic (GNU, Creative Commons) is available by looking up its
URL.

Anticonvulsant use in brain tumor patients
Hugh Moulding, MD

More than 200,000 patients are diagnosed with primary or metastatic brain tumors each year in
the United States. Of these patients, 20% to 40% will develop seizures at presentation, and another
20% to 40% will require treatment for seizures during their illness. Although the use of antiepileptic
drugs (AEDs) in patients who have had seizures seems reasonable, the issue of prophylactic AED
use for patients who have not had a seizure is an intensely debated subject.
At TJUH, we see the wide variety of practices in prophylactic use of anticonvulsants. Some physicians will use anticonvulsants and follow therapeutic levels, others will use a starting dose of AED
and not follow levels, and still others will not use AED at all. The reason for the discrepancy is
most likely multifactorial. There is little evidence to the benefit of AEDs in patients who have not
had seizures when considering the side effect profile of AEDs. However, give the litigious climate
of Philadelphia, many neurosurgeons are reluctant to leave a patient with an intracerebral lesion
without antiepileptic coverage. Additionally, many neurosurgeons are creatures of habit, trained
to practice a certain way, and have done so for many years during which “it has worked or them so
far.” A set of guidelines based on a literature search, where level I evidence is cited where possible,
would help physicians to be more comfortable about changing their practice.
http://commons.wikimedia.org/wiki/Image:Drug_
ampoule_JPN.jpg
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Since 2000, there have been practive guidelines
in place approved by the American Academy of
Neurology (see Ref 3) based on peer reviewed
publications with level I evidence. Despite these
practice parameters a recent survey reported
that 81% of neurosurgeons and 53% of neurologists prescribed antiepileptic drugs (AEDs)
prophylactically.
For the 20-40% of patients diagnosed with a
brain tumor who have experienced a seizure,
prophylactic use of AEDs is universally accepted.
Seventy percent of brain tumor patients
presenting with seizures will suffer recurrent
seizures regardless of tumor type. However,
patients that have not had a seizure still remain
at risk and 20-45% will develop seizures. Some
factors that have been shown to increase the
likelihood of developing seizures are:
1. Tumor location, most likely in frontal,
parietal or temporal lobes, especially
parasagital meningiomas (74% seizure
prevalence).
2. Number of tumors: increased number of
tumors correlates to higher seizure risk.
3. Tumor histopathology: Slow growing
tumors are at increased risk.
4. Age: younger patients more likely to seize.
One factor that is conspicuously absent from
the list above is AED use. Of the twelve studies
of Level I & II data that examined this question,
only one reported a significant difference in
seizure frequency and this favored the nonAED group having a lower seizure risk. A
meta-analysis performed on the four Level I
studies showed an Odds Ratio of 1.09 with no
statistical significance (p=0.9). Furthermore
AED use is not benign; 23.8% of these patients
experience side effects that warranted change
or discontinuation of the AED. These side
effects included rash (14%), nausea and
vomiting (5%), encephalopathy (5%), and
myelosuppression (3%).
References
1.

Sperling MR, Ko J: Seizures and brain tumors. Seminars in
Oncology. 33(3):333-41, 2006.

2.

Stevens GHJ: Antiepileptic therapy in patients with central
nervous system malignancies. Current Neurology and
Neuroscience Reports. 6(4):311-8, 2006.

3.

Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter:
anticonvulsant prophylaxis in patients with newly diagnosed
brain tumors: report of the quality standards subcommittee
of the American Academy of Neurology. Neurology.
54:1886-93, 2000.
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Cervical spondylotic myelopathy
Amgad Hanna, MD

We attempt to address the literature
controversies regarding this topic, the severity
of myelopathy, and the indications for surgery.

Online search for resources

http://commons.wikimedia.org/wiki/Image:The_
Thinker_wideshot.jpg

Cervical spondylotic myelopathy is a common
cause of major morbidity in middle-aged and
elderly people. Various functional classifications are used to evaluate patients with cervical
spondylosis. They are based on pure clinical
data, and are used as a method of evaluation of
the patient’s progress during the course of the
disease. None of these classifications defines
criteria for the indication for surgery.
Patients with cervical myelopathy may be
managed either conservatively or surgically.
Conservative management includes medications (e..g, non-steroidal anti-inflammatories
or corticosteroids), cervical orthotics, physical
therapy, or injections. Surgery includes anterior and/or posterior decompression and/or
fusion.
There remains considerable uncertainty
regarding the decision to operate and the
timing for surgery. This is left to the surgeon’s
discretion in most of the cases. Most surgeons
would agree that patients with mild myelopathy should be managed conservatively and
patients with severe myelopathy should be
managed surgically. There is a large gray zone
of moderate myelopathy where surgeons may
decide about surgery or conservative management. The definition of mild, moderate, or
severe myelopathy is vague in literature.
The timing of surgery is also controversial
in literature. Advocates of early surgery try
to stop disease progression, prevent further
clinical deterioration of the patients, and prevent the risk of acute deterioration with neck
injuries (central cord syndrome). Advocates
of late surgery try to delay the potential
complications of surgery like adjacent level
disease, spinal cord injury, cerebrospinal fluid
leak, infection, bleeding, and possible clinical
deterioration.

1. National guideline clearinghouse. We
searched for “cervical myelopathy”. No
guidelines were found for the management
of cervical myelopathy. Related guidelines
were found for cervical radiculopathy:
Review criteria for cervical surgery for
entrapment of a single nerve root. Olympia
(WA): Washington State Department of
Labor and Industries; 2004 June. 1p. The
article states that “Cases of myelopathy
should be referred for physician review”.
2. The Cochrane Library. We searched for “cervical myelopathy”. One article was found:
Cochrane review on the role of surgery in
cervical spondylotic radiculomyelopathy.
Fouyas I, Statham P, Sandercock P. Spine
2002; 27 (7): 736-47
3. Medline search: www.ncbi.nlm.nih.gov.
We searched for “management of cervical
myelopathy”; 104 articles were found

Summary of findings
There are no current guidelines for the management of cervical spondylotic myelopathy.
Several articles (1,2) discussed the prognostic
factors and presented surgical outcomes. These
articles presented conflicting results as far as
the prognostic significance of signal changes
on MRI, age, and duration of symptoms.
Other studies discussed the indications and
outcomes of different surgical approaches.
Again, conflicting results were found. Fouyas
et al. found no significant longterm differences
between surgery and conservative management3. Houten, Kim, Medow, Komotar, and
Sekhon showed good results with surgical
decompression 2, 4-7. However, there was no
comparison to conservative management.

Guidelines
The two articles selected are references 2 and 3.
Reference 2: Houten, Cooper (2003)
Full reference: Laminectomy and posterior cervical plating for multilevel cervical spondylotic
myelopathy and ossification of the posterior
longitudinal ligament: effects on cervical alignment, spinal cord compression, and neurological outcome. Houten J, Cooper P. Neurosurgery
2003; 52 (5): 1081-8

JHN JOURNAL
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Results

- Multilevel cervical laminectomy and
fusion for cervical spondylotic myelopathy provide minimal morbidity, excellent decompression, immediate stability,
prevent kyphosis, and precludes further
spondylosis.
Strengths

- Combined clinical and radiological criteria for outcome after surgery.

Final Guideline			
This guideline targets mainly neurosurgeons
and orthopedic spine surgeons who need to
decide for their patients whether to proceed
with surgical or conservative management. It
also targets primary care physicians to guide
them as to which patients need to be referred
for surgery.
Evaluation of the severity of myelopathy:

- Thirty months follow up.

The following scoring system is proposed to
evaluate the severity of cervical myelopathy:

Weaknesses

Comments

- Retrospective study.
- Small number of patients (38).
- No comparison group with conservative
management.
- No consideration for bony fusion vs
pseudoarthrosis.

Reference 3: Fouyas, Statham, Sandercock
(2002)
Full reference: Cochrane review on the role of
surgery in cervical spondylotic radiculomyelopathy. Fouyas I, Statham P, Sandercock P.
Spine 2002; 27 (7): 736-47

• This is the first grading system to include
both clinical and radiological data.
• Mild to moderate symptoms: mild pain or
numbness. Severe symptoms: severe pain
or numbness, loss of dexterity, difficulty in
walking.

2

No Signs

0

Mild to Moderate Signs

1

Severe Signs		

2

No stenosis

0

Moderate Stenosis

1

Severe Stenosis		

2

No signal changes
on MRI

0			

Signal Changes on MRI

2		

Total score 1-3: Conservative management. Total score 4-8: Surgery.

Results

clinical scenario, progression of the disease,
and co-morbidities.
References
1.

Effect of intramedullary signal changes on the surgical
outcome of patients with cervical spondylotic myelopathy.
Suri et al. Spine J 2003; 3 (1): 33-45

2.

Laminectomy and posterior cervical plating for multilevel
cervical spondylotic myelopathy and ossification of the
posterior longitudinal ligament: effects on cervical alignment, spinal cord compression, and neurological outcome.
Houten J, Cooper P. Neurosurgery 2003; 52 (5): 1081-8

3.

Cochrane review on the role of surgery in cervical spondylotic radiculomyelopathy. Fouyas I, Statham P, Sandercock
P. Spine 2002; 27 (7): 736-47

- Prospective randomized trials.
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Surgical management of cervical myelopathy: indications
and techniques for laminectomy and fusion. Komotar R,
Morcco J, Kaiser M. Spine J 2006; 6 Suppl: S 252-67

7.

Posterior cervical decompression and fusion for circumferential spondylotic cervical stenosis: review of 50 consecutive
cases. Sekhon L. J Clin Neurosci 2006; 13 (1): 23-30

Does the treatment of carotid
dissection require anticoagulation
with coumadin or is antiplatelet
therapy equally efficacious?
Aditya Pandey, MD

• This is just a guideline. Cases need to be
managed individually, based on the whole

Severe Symptoms		

- Patients represented in the studies had
mainly mild functional deficit. They do
not represent the population that usually
benefits from surgery, who have moderate to severe myelopathy.

Surgical management of cervical myelopathy: indications
and techniques for surgical corpectomy. Medow J, Trost G,
Sandin J. Spine J 2006; 6 Suppl: S 233-41

• The recommendations are based on the best
available literature.

1

Weaknesses

5.

• Moderate stenosis: Mid-sagittal diameter:
10-12 mm. Severe stenosis: Mid-sagittal
diameter: < 10 mm.

Mild to Moderate Symptoms

Strengths

Indications for circumferential surgery for cervical spondylotic myelopathy. Kim P, Alexander J. Spine J 2006; 6 Suppl:
S 299-307

• Mild to moderate signs: hyper-reflexia,
Hoffman’s or Babinski’s signs, mild weakness. Severe signs: significant weakness,
spasticity.

Table 1. Score System
No Symptoms
0

- No significant difference in long term outcome between surgical and conservative
management for cervical myelopathy.

4.

http://commons.wikimedia.org/wiki/Image:Blut-EDTA.jpg

Vessel dissection represents injury to the wall
of the vessel either from the luminal side or
adventitial (outside) side. Extracranial carotid
and vertebral artery dissections represent the
second leading cause of stroke in young adults.
Its incidence is 2-3 persons/ 100,000/ year.
The mechanism of developing stroke within
this patient population is from clot formation
at the site of the injury to the vessel. The
causes of carotid dissection are numerous, but
it most commonly occurs due to a traumatic
injury in an individual who has weakened
vessels. To prevent such an event, patients are
started on blood thinners: either antiplatelet
(aspirin) or coumadin.
Depending on physician and surgeon preference, different anticoagulation therapy can be
used for the same type of patient with carotid

8
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dissection. Those who use coumadin do so
since they have had success in treating carotid
dissection patients without stroke formation.
The same is true of physicians utilizing antiplatelet therapy. The use of coumadin not only
requires that patients have frequent blood tests
to show level of blood thinning but also that the
bleeding risks associated with it are higher. The
goal of this analysis is to present the evidence
for using coumadin versus aspirin in the treatment of carotid dissection.

Benefits of Full Anticoagulation
• anticoagulation leads to the prevention of
stroke from the formation of clots at the site
of the vessel injury

Complications of Full Anticoagulation
• anticoagulation could lead to further bleeding into the brain

Specifics of Search
Clearinghouse
• Search of National
Guidelines revealed one review but no
specific guidelines
• Search of the Cochrane Database did not
reveal any position statements on the
subject
• The following key term searches on Pubmed led to numerous articles on the subject
of treating carotid dissection with anticoagulation:
- “Extracranial carotid dissection”
- “Treatment of extracranial carotid dissection”
- “Anticoagulation for extracranial carotid
dissection”
Results
1. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev. 2000;
(4): CD 000255
Strengths

- comprehensive review of case controlled
studies and case series
- applies to carotid dissection patients who
had undergone either anticoagulation
with coumadin or antiplatelet therapy
Limitations

- No statistically significant difference in
outcome (mortality/disability) between
patients on antiplatelet therapy versus
those on anticoagulation (coumadin)
- No difference in the occurrence of intracerebral hemorrhage between the two
groups (0% for antiplatelet group and
0.5% for anticoagulation group)

Conclusion
- no statistically significant difference in
outcome or complication when comparing the anticoagulation versus the
antiplatelet group of patients
2. Cervical Arterial Dissection: time for a
therapeutic trial? Stroke. 2003 Dec; 34 (12):
2856 – 60
Strengths

- prospective enrolled patients with carotid
and vertebral dissections
- large number of patients (n=116)
- comparison of aspirin vs. anticoagulation
Weaknesses

- not a randomized control trial
- N might not be large enough to a small
statistically significant difference
Summary

- Canadian Stroke Consortium prospectively enrolled patients with extra-cranial
dissections and followed patients for
one year. The endpoints being evaluated included: TIA, Stroke, or Death.
105 patients had complete follow up. In
patients treated with anticoagulation the
event rate was 8.3% versus those treated
with aspirin where the event rate was
12.4%. While there was an absolute difference of 4.1%, this difference was not
statistically significant.

Conclusion
There were no statistically significant differences between the outcome rates of patients on
ASA versus those on anticoagulation.
1. Dissection of Cervical Arteries: Long-term
follow-up study of 130 consecutive cases.
Cerebrovasc Dis. 2006; 22 (2-3): 150-4

- no randomized control trials included in
this study (No RCT have been performed
addressing this issue)

Strengths

Summary

- Comparison of ASA vs. anticoagulation

- 26 eligible studies were reviewed (327
patients)

- Prospective Study
- N=130 cases

Summary

- 130 patients with angiographically
proven cervical arterial dissection were
followed for the events of stroke and
death. There was no significant differences in outcome were found when
comparing patients on aspirin versus
the patients on anticoagulation.

Conclusion
In patients with proven carotid dissections,
there is no difference in outcome between
patients treated with ASA vs. those treated with
anticoagulation.
1. Outcome of extracranial cervicocephalic
arterial dissections: A follow-up study.
Neurol Res. 2002 Jun; 24 (4): 395-8
Strengths

- comparison of ASA vs. anticoagulation
- long term f/u (nearly 10 years)
Weaknesses

- not a randomized control trial
- small patient population (n=27)
Summary

- 27 patients with extracrainal CAD who
were treated and followed by the stroke
service. Outcome was assessed using the
modified Rankin Score and recurrent
stroke and TIAs were also recorded. The
outcome was favorable with either antiplatelet or anticoagulation.

Conclusion
Either antiplatelets or anticoagulation are
equally effective in preventing strokes after
carotid dissection,
Final Guideline
In individuals with a proven extracranial
carotid dissection, aspirin therapy should be
initiated instead of coumadin. The current
literature on the subject shows no statistically
significant difference in outcome of individuals
treated with aspirin versus those treated with
coumadin in the setting of carotid dissection.
While the risks with coumadin are not higher,
it still requires evaluation of the INR for accurate dosing. Such is not the requirement of
antiplatelet therapy. In addition other medications (cimetidine) can affect the metabolism of
coumadin thus leading to inappropriate levels
of anticoagulation. Thus antiplatelet therapy is
an effective method of preventing strokes in
individuals with carotid dissection.

Weaknesses

- not a randomized control trial
- F/U only 6 months

Published by Jefferson Digital Commons, 2009
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Would a standardized protocol for the
inter-hospital transport of critically ill
patients alter outcomes?
Jack Klem, MD

The rapid evolution of healthcare technology
has created a disparity among hospitals and
thus led to the establishment of highly specialized quarternary institutions, termed “Centers
of Excellence.” This has created a need for the
systematic triage and transport of certain critically ill patients that would not receive adequate
care at a community hospital. Emergency
Medical Services (EMS) has made the transport
of patients a national issue due to regionalization, specialization, and facility designation
by payers. Despite this, there exists a paucity
of guidelines to direct the appropriate flow of
patients to higher levels of care.
Diversity exists amongst transport teams
and overall resource allocation. Interfacility
transport is provided by a variety of levels and
types of personnel and agencies. The medical
condition of the patient is not always matched
appropriately with the acuity of care provided
by the transport team. Less severely ill patients
are sometimes intubated and ventilated solely
to facilitate ease and safety of transport.
In addition, the disease process of a particular
diagnosis is not always understood prior to
dispatching the appropriate means of transport
(ie, air vs. ground). For example, patients
with suspected aneurysmal subarachnoid
hemorrhage require the most expeditious
mode of transportation due the high risk of rerupture in the acute period. Moreover, certain
diagnoses such as cerebellar hematoma with
deteriorating neurological function require
immediate transfer to the operating room with
no need for an available ICU bed. Recognition
of these “hyperacute” scenarios are critical to
patient outcome.
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Guidelines are necessary to standardize interfacility transport on at least the regional level.
Several steps must be analyzed in order to
establish a systems-based protocol for interfacility transfer. The type of transfer must be
established (ie, hospital to hospital, rehab to
hospital, clinic to hospital, etc.) Next, provider
capabilities must match the patient’s current
and potential needs in order to provide safe and
effective care during transport. This has been
shown to impact outcomes in the transport of
pediatric patients. On an administrative level,
certification of necessity for transfer is a requirement for reimbursement by Medicare and
Medicaid. This is directed by federal legislation
outlined in the Consolidated Omnibus Budget
Reconciliation Act (COBRA) and Emergency
Medical Treatment and Labor Act (EMTALA).
In summary, all of these factors must be integrated in order to develop a regional or even
national plan for interfacility transport. This
shall streamline resource allocation and potentially improve outcomes

Online Search
1. National Guidelines Clearinghouse was
queried for “patient, hospital transport” and
“interhospital transport”
2. Google was queried for “patient transport,
guidelines” and “hospital transport”
Study #1: Warren at al (2004)
Full reference: Warren et al. Guidelines for
the inter- and intrahospital transport of critically ill patients. Crit Care Med 32:1 (2004)
256- 262.
Purpose

- Development of practice guidelines for
inter- and intrahospital transport of the
critically ill patient in order to establish
an efficient, organized process supported
by appropriate equipment and personnel.
This would ultimately enhance patient
safety.
Methods

- Synthesis of prospective clinical outcome
studies, retrospective reviews, and anecdotal reports by a task force of experts
providing consensus opinion.
Results

- A multidisciplinary team of physicians,
nurses, respiratory therapists, hospital
administration and the local emergency
medical service must justify and coordinate the process by conducting a needs
assessment of the referring hospital or
clinic, asking whether transport is likely

to alter the management or outcome of
the patient. A patient must have a preliminary diagnosis that can be further
refined and ultimately treated at a center
that offers specialized diagnostic capability. Receiving hospitals should then proceed with a formalized plan addressing
the following points:
- pretransport coordination and communication
- transport personnel
- transport equipment:
- monitoring during transport
- documentation: The patient’s medical record and relevant laboratory and
radiographic studies must be copied for
the accepting facility. It is also suggested
to perform a COBRA/EMTALA checklist to ensure compliance with federal
regulations.
- The above five points should be evaluated and refined regularly by the hospital
using a standard quality improvement
process. Many of the specific details from
these guidelines are incorporated in the
final guidelines below.

Conclusions
When services are required that exceed available resources at a particular hospital or clinic,
a patient will be ideally transferred to a facility
that has the necessary resources. The decision
to transport a critically ill patient is based on
the potential benefits (ie, higher level of technical/cognitive/procedural care) and weighed
against the risks. Justification for transport
must be established and several points must
be addressed to ensure safe and efficient
transfer.
Strengths of study

- Article provides clear, comprehensive
guidelines discussed above for transporting patient within and between hospitals.
Not only do these guidelines comply with
federal regulations, but they also illustrate
the importance of having an organized,
efficient and standardized protocol that
can be followed by any hospital.
- Details of transport such as appropriate
equipment and personnel are described
in order to ensure utmost safety for the
patient being transported. Again, this is
an effort to standardize the entire process
in order to eliminate “system-based”
mistakes. For example, there exists much
variability in the acuity of care provided
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by transport teams due to improper
triage, insufficient equipment, and
inexperienced personnel. To resolve this,
this article takes the stance that patient
transportation must be subjected to the
same rigors as the aviation industry in
eliminating systems errors by establishing
a universal set of guidelines.
Weaknesses of study

Conclusion

Conclusions

Insufficient data exists regarding the mortality,
morbidity, and risk factors associated with the
interfacility transport of critically ill patients.
Further research is necessary to understand
which patients are most at risk while being
transported. Recognizing the types of events
that can occur is an important step in patient
preparation and planning.

Important factors for improvement were better
overall communication between the referring/ receiving hospital and strict adherence to
checklists/ published protocols.

- This is really the first effort in the literature
to establish a universal set of guidelines
and, as a result, no outcome studies are
yet available.

Strengths of study

- This article also assumes that every hospital has the same basic resources available
to standardize patient transport. This
becomes an issue with the transport of
critically ill patients where the accepting
hospital may have to provide the appropriately staffed and equipped transportation team.

Weaknesses of study

Study #2: Fan et al (2006)
Full reference: Fan et al. Outcomes of interfacility critical care adult patient transport: a
systematic review. Critical Care 10 (2006) 1-7.
Purpose

- Determine the adverse events and important prognostic factors associated with
interfacility transport of intubated and
mechanically ventilated adult patients.
Methods

- A systematic review of multiple databases
yielded 5 case-series comprising of a total
of 245 patients. Two of the case-series
were prospective in design.
Results

- Data was synthesized in a qualitative
manner due to significant heterogeneity
in study population, outcome events, and
results. The most common indication for
interfacility transport was a need for specialized investigations and interventions.
Transport modalities included air (66%),
ground (31%) and commercial aircraft
(3%). Transport teams included a physician in 3 of the 5 studies. Death during
transport was rare (n=1) and no other
adverse events or significant therapeutic
interventions were reported during
transport. Of note, one study reported
a 19% (28/145) incidence of respiratory
alkalosis upon arrival.
-

Published by Jefferson Digital Commons, 2009

- First attempt to study outcomes of interhospital transport of critically ill patients

- This is similar to a meta-analysis that
combines different levels of evidence
(ie, three retrospective studies plus two
prospective studies) and attempts to draw
meaningful conclusions. There must be
one prospective trial that addresses the
same patient population.
- This article looks only at adverse outcomes that occur while a patient is en
route rather than considering the period
just before and after transport. This under
reports situations, for example, where
some patients begin to deteriorate and
are intubated immediately upon arrival.
Study #3: Ligtenberg et al (2005)
Full reference: Ligtenberg et al. Quality of
interhospital transport of critically ill patients:
a prospective audit. Critical Care 9 (2005)
446-51.
Purpose

- Determine the adverse events and important prognostic factors associated with
interfacility transport.
Methods

- prospective study describing 100 consecutive ICU transfers, of which 65%
were mechanically ventilated and 38%
on vasoactive drugs.
Results

- Data was collected on adverse events
before, during, and after transport. 34%
of patients incurred adverse events with
6 deaths being reported within the first
24-hours after arrival. This study was
different because not all patients were
intubated and not all were accompanied
by a physician as was the case in Fan et
al. (2006).

Strengths of study

- Describes a single, prospective study
involving the transfer of 100 patients into
only one university center. This eliminates the inherent flaws of a combining
several different studies.
- Information regarding adverse events
was collected for 24-hours after arrival.
Weaknesses of study

- There was no stratification of diagnoses.
For example, there is no discussion as
to why each of the 34 adverse events
occurred. For example, was this due to
inadequate stabilization of the patient’s
medical condition prior to transport,
due to inadequate care provided during
transport, or merely patient disease?
Final Guidlines for inter-hospital transport of
critically ill patients
Diagnosis

- Patient requires emergent surgical intervention that will occur immediately upon
arrival to the accepting institution. This
applies to diagnoses such as cerebellar
hematoma, EDH, or SDH in the setting
of a rapidly deteriorating patient. This
defines the highest acuity transfer wherein
communication between physicians, OR
staff, and transport personnel is critical to
transporting a patient directly to the holding area and/or operating room in order
to save the patient’s life. Expending time
to “make a bed” at the accepting institution will gravely impact the patient’s
outcome and thus must be overlooked in
order to transport the patient as rapidly as
possible to the operating suite.
- Patient requires emergent surgical
intervention within 24-hours of arriving
to the accepting institution. This applies
to diagnoses such as SAH where cerebral
angiogram with definitive treatment is
performed within 24-hours of arrival.
The caveat here is that these patients may
develop hydrocephalus which sometimes
cannot be treated at a referring institution
and therefore requires emergent transport. Another diagnosis is cauda equina
where a patient will require an MRI followed by surgery within 24-hours.
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- Patient requires urgent imaging studies that may or may not require surgery
in the setting of a neurologically and
medically stable patient. This applies to
diagnoses such as cervical spine trauma
where the patient’s neurological status
is not changing. For example, a patient
with facet dislocation requiring traction
and/or reduction.
- Patient requires observation in a
neurosurgical ICU, but remains stable
neurologically. This applies to diagnoses
such as a basal ganglia hemorrhage.
- Patient does not have an established
diagnosis due to lack of MRI, angiography, etc. at the referring institution but
remains neurologically stable.
PRE-TRANSPORT COORDINATION
Communication is Key

- Establish continuity of care by physician-to-physician and nurse-to-nurse
review of patient condition and current
treatment plan. Receiving physician
should provide advice to aid in pretransport stabilization and provide advance
medical treatment when appropriate (ie,
Mannitol, steroids, antiepileptic in setting
of aneurysmal SAH with hydrocephalus).
The appropriate arrangements should
be made at the receiving institution to
avoid delays in definitive treatment (ie,
operating room standby). The mode
of transport must also be established.
Communication is especially critical in
the setting of the first set of diagnoses
described above.
TRANSPORT PERSONNEL
Education = Empowerment to Intervene

- A minimum of two people should accompany a critically ill patient consisting of a
critical care nurse plus a technician. In the
case of an unstable patient, it is recom-
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mended that a physician with training in
airway management and ACLS be present. When this is not possible, some
hospitals prophylactically intubate those
patients who have a high risk for becoming unstable en route. In the setting of
elevated ICP, the transport personnel
must understand the diagnosis and
means of controlling ICP during transport. For example, most patients arrive
flat and supine which is not the optimal
position for a patient with impending
hydrocephalus. Transport personnel
cannot serve as technicians, but must be
aware of the patients diagnosis in order
to best maintain and even optimize the
patient prior to arrival.

The above five points serve as a general set of guidelines that should be
evaluated and refined regularly by
the hospital using a standard quality
improvement process. The hospital
transfer center should develop a checklist for each of the five points described
above and follow the same steps for each
and every transfer. Attention to details
by methodically following the same
steps in each situation will hopefully
minimize “systems” mistakes and thus
not only improve efficiency, but also
maximize safety.

TRANSPORT EQUIPMENT
Continuity of Care

- The patient must be maintained using the
same monitors and drugs (if necessary)
as are present in the ICU. A blood pressure monitor, pulse oximeter, cardiac
monitor/ defibrillator, basic rescucitation
drugs, and a portable mechanical ventilator when indicated.
DOCUMENTATION:
What is the Goal of Transfer?

- The patient’s medical record and
relevant laboratory and radiographic
studies must be copied for the accepting
facility. It is also suggested to perform a
COBRA/EMTALA checklist to ensure
compliance with federal regulations. This
includes documentation of initial medical
evaluation and stabilization procedures,
informed consent disclosing risks and
benefits of transfer, and documentation
of physician-to-physician communication with the names of each physician
involved. Financially motivated transfers
are illegal.
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Spinal Cord Stimulators:
an Introduction
Steven Falowski, MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

Background
Pain can be divided into two broad categories, nociceptive pain and neuropathic pain. Nociceptive
pain is a dull, throbbing pain which results from irritated nerves after physical tissue injury. This is
seen commonly in cancer or after a fracture. Nociceptive pain is amenable to treatment with pain
medications such as opioids and/or anti-inflammatories. Neuropathic pain is described as burning,
shooting, or shocking pain. This type of pain results from nerve damage or abnormal nerve conduction such as pain exhibited with failed back syndrome, post surgical pain, neuromas, shingles, and
complex regional pain syndrome (previously called RSD or causalgia). Neuropathic pain tends to
be resistant to treatment with pain medications. Neurostimulation has been an effective treatment
option for the management of chronic neuropathic pain. It is a reversible therapy which can even be
tested before permanent implantation.
Spinal cord stimulation (SCS) is an adjustable, non-destructive, neuromodulatory procedure which
delivers therapeutic doses of electrical current to the spinal cord or to a targeted nerve. This lowvoltage stimulation can block the transmission of pain. The enthusiasm for SCS began with the
introduction of the gate control theory for pain control by Melzack and Wall in 1965 1.They noted
that stimulation of large myelinated fibers of peripheral nerves resulted in paresthesias and blocked
the activity in small nociceptive projections. In other words, pain receptors compete with each other
and with other sensory afferents. Appropriate stimulation of a “rival” afferent can effectively block a
pain signal. This is why rubbing your chin after its been hit relieves the pain – the bump is still present,
but the rubbing blocks it. The SCS system is implanted in a space surrounding the spinal cord, called
the epidural space, where it stimulates the dorsal columns which can mask the sensation of pain by
producing a tingling sensation.

Figure 1
A patient that had persistent
neuropathic pain in his back and his
legs despite anterior and posterior spinal
reconstructive surgery.

Patient Selection
Some of the criteria listed below can be used to determine candidates for neurostimulation:
• Conservative therapies have failed to adequately help the pain.
• Further traditional surgical intervention is not indicated.
• No serious untreated drug habituation for the pain condition exists.
• Psychological evaluation and clearance for implantation have been received, sorting out
untreated depression or anxiety, addiction, or other behavioral disorders.
• No medical issues exist that would present problems with doing the surgery.

Indications
The most common indications include post-laminectomy syndrome or failed back surgery syndrome
(FBSS), complex regional pain syndrome (CRPS) or reflex sympathetic dystrophy (RSD), ischemic
limb pain, and angina. Scattered reports regarding the treatment of intractable pain due to other
causes including visceral/abdominal pain, cervical neuritis pain, spinal cord injury pain, post-herpetic
neuralgia, and neurogenic thoracic outlet syndrome have also appeared in the literature.

Surgical Technique
The procedures are most commonly performed by neurosurgeons or anesthesiologists specializing
in pain management 2-5. A lead is temporarily utilized to cover a wide area for pain control. The
lead, or electrode, is implanted into the epidural space. The lead is attached to a power source called
the pulse generator (or commonly known as the battery). This is then connected to an outside or
external system which is held in place by sterile dressings. The unit is then tested for efficacy during
a screening period, which is usually 3-10 days.

Published by Jefferson Digital Commons, 2009

Figure 2
The patient received an implanted
transverse tripole electrode in the thoracic
spine. The new electrode has the ability
of focusing the electrical field into the
dorsal column to maximize the paresthesia
into the back while avoiding painful
stimulation of the nerves into the ribs.
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If relief is obtained at this point, the system may
be implanted permanently. The stimulator is
usually placed in an area where the skin will
not be irritated and the unit will not be pressing against bone. The abdomen and buttocks
are common locations.

Benefits
Neurostimulation has been shown to have a
50% improvement in pain relief, reduce the use
of medications, and allow the person experience
an improvement in their quality of life 6-7. These
benefits are expected to increase with improvements in the technology and in understanding
of how pain signals are generated and gated in
the nervous system. It is important to realize
that neurostimulation is a treatment option
along the continuum of pain control.

Potential Adverse Effects
Surgical risks associated with an implant include
hematoma, infection, and possible leakage of
cerebrospinal fluid. Because this is a device,
there can be malfunction of the hardware or can
have disruption in the settings by other signals;
for example, patients with an SCS are advised
to turn it off before going through an anti-theft
device in a retail store; additionally, patients
with an SCS can not undergo a magnetic resonance imaging (MRI) scan.
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Summary
Spinal cord stimulation therapy has been available and approved for over two decades. In
the last five years, there have been significant
advances in the technology: smaller, rechargeable batteries; better electrodes; and improved
implantation techniques. More physicians are
adapting this therapy in their practice for pain
management and we are effectively improving
patients’ lives.
The treatment of chronic pain remains challenging. Experience in the technique and the
equipment has made SCS a much more reliable and safe modality. Like all the modalities
performed for chronic pain management,
its results are favorable. It is important to
remember that the goal of neurostimulation is
to reduce pain, rather than to eliminate pain.
Very few other invasive modalities can claim
this success rate with a few years of follow-up.
Spinal cord stimulation has earned a well established and firm role in contemporary chronic
pain management.
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Surgeon Opinions on Use of Epidural
Steroids in Treatment of Lumbar Disk
Disease: Results of an Online Survey
John K. Ratliff MD, Mitchell Maltenfort PhD, Bryan Lebude
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

Introduction
“Standard of care” can vary along regional and specialty lines; it is common to discover that a
local “standard” can be different somewhere else. Opinions may differ between pain management
specialists, primary care physicians, and spine surgeons with regard to use of conservative
treatment modalities.
Opinion within a given group of practitioners, however, should converge. Local differences
between hospitals may exist, but conferences, professional journals, and national boards for
certification are mechanisms that should act to maintain homogeneity within a professional
group. It could be expected that commonly utilized treatment approaches within a well defined
group of sub-specialists should converge.
One of the more common non-surgical options for herniated lumbar spinal discs is epidural
steroid injections (ESIs). Patients may be referred to pain management centers for lumbar ESIs
by their primary care physician or perhaps after consultation with a surgical specialist. We
sought to assess the opinion of practicing spine surgeons with regard to timing and use of lumbar
ESIs as a part of a conservative treatment approach to both lumbar disk herniations (HNP) and
lumbar degenerative disk disease (DDD).

Table 1.
1. When in the treatment plan do you
consider ESIs for patients with a lumbar
herniated disc?

a. after 6 weeks of conservative care
b. after 6-12 weeks of conservative care
c. after 3-6 months of conservative care
d. after greater than 6 months of conservative
care

2. What is the average number of ESI
a. 1 treatment regimen
treatment cycles that patients with lumbar b. 2 treatment regimens
herniated discs normally receive before
c. 3 treatment regimens
considering alternate treatments?
d. 4 treatment regimens or more

The definition of “conservative therapy” is
unclear, although use of same as a control
arm in prospective studies of surgical efficacy
is commonplace. We sought to assess whether
practicing spine surgeons would agree upon
treatment protocols in their approach to
treatment of lumbar degenerative disease and
lumbar disc herniations. Lack of agreement on
use of this tool in conservative management
of lumbar disease could imply greater
divergence in broader use of conservative
treatment modalities.

Methods
An online survey was announced and made
available on www.spineuniverse.com, a portal
site for information on therapies for spinal
conditions. Sixty-one surgeons responded
to the survey. Because participants were selfselected, we must be cautious about whether the
results can be generalized. The survey questions
are presented in Table I. Sixty-one surgeons
responded.
There was broad divergence in all responses.
The only clear majority was the decision to
consider ESIs after 6 weeks of conservative
treatment in lumbar HNP (Figure 1). In both
HNP and DDD, the number of ESI regimens
administered before considering surgical alternatives followed the same pattern: surgeons
were likelier to favor smaller numbers of cycles,
and going as far as 3 or 4 regimens was unlikely
(Figure 2). Otherwise, there was no clear pattern
in how ESIs were used (Figures 3, 4 and 5).

b. Often (50-75% of the time)

Bowker’s test of symmetry was used to assess
whether surgeons were likely to use ESIs the
same way in HNP and DDD. Statistically
significant differences were found in the length
of time before ESIs were considered (Figure 1;
p < 0.01) and the length of time before invasive
surgical options were considered (Figure 3; p <
0.05). These results suggest that surgeons tend
to change treatment options earlier in HNP
than in DDD.

c. Sometimes (25-50% of the time)

Discussion

d. Rarely (<25% of the time)

If the self-selected response sample is biased,
we might assume that the bias would tend to
homogenize the reported opinions. Conversely,
a small population sample may

3. How long are patients with lumbar
herniated discs treated with conservative
care and ESIs before more invasive
treatment options are considered?

a. up to 6 weeks

4. How frequently do you consider using
epidural steroid injections (ESIs) in
your treatment of patients with lumbar
herniated disc?

a. Frequently (>75% of the time)

5. How many ESIs are normally considered
in a treatment regimen for patients with
lumbar herniated discs?

a. 1 injection

b. 6-12 weeks
c. 3-6 months
d. Patient directed

b. 2 injections
c. 3 injections

Published by Jefferson Digital Commons, 2009
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Survey Responses
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0%
After 6 weeks of
conservative care

After 6 to 12 weeks of
conservative care

After 3 to 6 months of
conservative care

After 6 months of
conservative care

4

3

2

1

Figure 1

Figure 2

When in the treatment plan do you consider ESIs for patients with a lumbar
herniated disc?

What is the average number of ESI treatment cycles that patients with lumbar
herniated discs normally receive before considering alternate treatments?
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6-12 months

Rarely
(<25% of the time)

patient directed

Sometimes
(25-50% of the time)

Often
(50-75% of the time)

Frequently
(>75% of the time)

Figure 3

Figure 4

How long are patients with lumbar herniated discs treated with conservative care
and ESIs before more invasive treatment options are considered?

How frequently do you consider using epidural steroid injections (ESIs) in your
treatment of patients with lumbar herniated disc?
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HNP (n=49)
DDD (n=47)

60%

% of responses

50%
40%
30%
20%
10%
0%
i injection
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Figure 5
How many ESIs are normally considered in a treatment regimen for patients
with lumbar herniated discs?
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show more difference from the “true” mean
than would a larger sample. With these caveats,
we may state based upon our survey that there is
no clear consensus on how the role of epidural
steroids in treatment of patients with HNP or
DDD.

according to which surgeon assesses their case.
While there may be no significant difference on
outcome between three weeks or six months of
ESI treatment, there remains a potential real
impact on patient well-being and on medical
expenses incurred.

The potential consequence on patient care
is obvious. Treatment regimens given to
individual patients are effectively randomized

More importantly, this variance may also
complicate attempts to study the effectiveness
of new interventions. If “conservative” control

Published by Jefferson Digital Commons, 2009
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treatments vary from surgeon to surgeon, and
presumably from location to location, studies
using “standard conservative treatment” as
their control arm are suspect. It is possible,
though untestable, that these variations selfpropagate as surgeons base their choices on
both published articles and on communication
between colleagues.
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Case Report: Intramedullary Cervical
Spinal Cord Hemangioblastoma with an
Evaluation of von Hippel-Lindau Disease

Past Medical History

Hypertension, Diverticulits, Multiple Sclerosis, optic neuritis

Past Surgical History

Inguinal hernia repair, Colectomy, Re-anastomosis of bowel

Social History

Inguinal hernia repair, Colectomy, Re-anastomosis of bowel

Allergies

NKDA

The patient worked with physical therapy and
was discharged home on post operative day
number four. His post operative incisional pain
was controlled with Percocet. The patient was
also administered Valium and Neurontin to help
with the neck pain and parasthesias following
the surgery. The patient’s neurological exam on
discharge demonstrated mild numbness in the
right upper extremity and slight weakness in
right hand grip, with resolution of preoperative
sensory deficits in the lower extremities.
Motor exam was 5/5 in all other muscle
groups. Postoperative MRI demonstrated no
residual tumor with expected post operative
changes. Pathology was consistent with
hemangioblastoma. In follow up the patients
remaining right upper extremity numbness had
resolved and the patient was able to return to
work 8 weeks postoperatively.

Medications

Toprol, Beta Interferon

Discussion

Initial Neurological Exam

The patient’s exam was consistent with a decrease to light touch in
his bilateral lower extremities and right upper extremity. Pinprick
and proprioception were intact. Motor strength was 5/5 in all muscle
groups. There were no difficulties with tandem gait. Reflexes were 2+
throughout and symmetric. The patient had showed neither
Babinski’s nor Hoffman’s sign.

The decision to proceed with surgery was based
on the natural history of this tumor. It may
continue to grow and with further expanding of
the syrinx or cystic cavity may produce further
neurological deterioration. It can be anticipated
that the best time for surgery would be while the
patient has a strong neurological status and best
chance for recovery.

Steven Falowski MD, Ashwini Sharan MD, James S. Harrop MD, John K. Ratliff MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

History of Present Illness
MO is a 49 year old male with a history of multiple sclerosis who presents with a one year history
of progressive numbness in his shoulders bilateral and upper back. The patient describes occasional
sharp pains that radiate to his first three fingers on his right hand. He denies weakness, clumsiness,
difficulty walking, or bladder/bowel dysfunction. He describes no problems with handwriting, or
fine motor skills.

Hospital Course
A MRI of the brain was performed early in the course of symptoms demonstrating his known multiple sclerosis lesions without any changes. With continued worsening symptoms, further workup
included an MRI of the cervical spine which demonstrated a 1 cm homogenously enhancing intramedullary lesion at C2 with an associated cyst and syrinx.
Prior to surgical intervention, the patient was counseled on the risks entailed in the removal of a
spinal cord tumor. Based on the characteristics on the MRI, a diagnosis of hemangioblastoma was
favored and therefore the possibility of having von Hippel-Lindau (VHL) disease was discussed
with the patient. The patient underwent an MRI of the complete neuro-axis including brain and
spinal cord screening for any other lesions. An ultrasound of the abdomen was performed which
demonstrated no renal lesions, liver lesions, or adrenal masses. An ophthalmologic examination
demonstrated none of the stigmatisms associated with VHL.
Prior to surgical excision, an angiogram was performed for the potential to embolize any large vessels.
However, no tumor blush was appreciated during the angiogram.
The patient underwent a laminectomy from C1-3 to expose the spinal cord. Intra-operative ultrasound was used to isolate the borders of the nodule and define the cystic component. A dural incision
and midline myelotomy was performed. The tumor was removed en bloc and the cyst decompressed.
The tumor was noted to be significantly vascular. Intra- operative ultrasound was utilized to confirm
full resection. During removal of the tumor somatosensory evoked potentials were noted to decrease
by approximately 50% in all four extremities.
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Hemangioblastoma is a vascular neoplasm
of the central nervous system. It is the most
common primary neoplasm in the adult cerebellum, but is rarely a tumor of the spine1.
Hemangioblastoma may occur sporadically
or as a component of von Hippel-Lindau syndrome. Radiological findings such as associated
cyst, an associated syrinx, and/or surrounding
spinal cord reaction or edema2, 3 are helpful in
diagnosing hemangioblastoma. Thirty-two percent of patients with spinal hemangioblastoma
have von Hippel-Lindau syndrome. Symptoms
of spinal hemangioblastoma are similar to those
of other spinal canal tumors and include sensory
change, motor disturbance, and pain. Because
the presentation of spinal hemangioblastoma is
similar to that of other spinal canal masses, MRI
studies can be useful in suggesting a diagnosis2.
VHL is a rare genetic condition. The disease is
an autosomal dominant disorder carried on the
third chromosome with near complete penetration and variable expression4. The gene behaves
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Figure 1

Figure 2

Figure 3

T1 axial MRI post contrast

T1 sagittal MRI post contrastn?

T2 sagittal MRI

as a typical tumor suppressor gene. The age of
onset, as well as severity is variable. There are
various subtypes which characterize the risks of
developing renal call carcinoma, pheochromocytoma, and angiomatosis. Angiomas are the most
common presenting signs and symptoms of this
disease syndrome. Of note, only 20% of patients
with VHL develop pheochromocytomas.
Features of VHL can include hemangioblastoma’s in the cerebellum and spinal cord, as well
as angiomatosis in the retina and other organs.1
Other features include pheochromocytoma,
renal cell and pancreatic cysts, renal cell carcinoma, as well as café au lait spots. Neurological
sequeala and death arise from complications

Published by Jefferson Digital Commons, 2009

associated with central nervous system tumors,
as well as cardiovascular instability secondary
to a pheochromocytoma. Decrease in visual
acuity and blindness may arise as well5.
Work up for suspected VHL can include genetic
studies, as well as Vanillylmandelic acid levels
in urine. Imaging studies can include an MRI
of the brain and spinal cord, ultrasound and/or
CT of the abdomen, and ophthalmic exam with
ocular dopplers5. VHL is usually a progressive
disease and therapy should begin as soon as the
diagnosis is made. Surgical treatment is usually
indicated.
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Cervical Intramedullary Ganglioma
Harminder Singh MD, Ashwini Sharan MD, John K. Ratliff MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

A 48 year male presented to the ER with severe headaches which were episodic in nature and which
had been present for several weeks. Patient had a history of traumatic head injury (TBI) several years
prior. Otherwise, he was in good health with no significant past medical or surgical history.
On physical exam, patient was oriented x 3 with an intact cranial nerve exam. He had significant
upper and lower extremity spasticity with mild hand intrinsic weakness. His motor exam was otherwise unremarkable. His gait was very spastic. He had sustained lower extremity clonus, upgoing
toes, and increased tone in the upper and lower extremities. His sensation was intact to light touch,
pinprick, proprioception and temperature.
What imaging studies would you order?
A CT scan of the brain was initially obtained secondary to the severity of the patients’ headaches and
past history of TBI.
The head CT revealed an old lacunar infarct in the left basal ganglia. There was no intracerebral hemorrhage or extra axial collection. However, in the spinal cord at the level of C1, an 8 mm hypodensity
was noted.
This prompted an MRI of the cervicomedullary junction. An ovoid, 1.1 x 1.0 x 1.7 cm intramedullary
lesion was seen expanding the cervical cord at the C1-2 level. It was hyperintense on T2-weighted
images and hypointense on T1 weighted images, and demonstrated some mild curvilinear enhancement within the lesion.

Figure 1
Pre-op axial non-contrast CT head showing
hypodensity within the spinal cord

What is your differential diagnosis? Would you perform any further imaging?
These radiographic findings were consistent with a low grade tumor such as an astrocytoma. An
ependymoma or cord metastasis were considered less likely.
No evidence for primary malignancy was found on imaging of the chest, abdomen and pelvis.
Imaging of the entire neural-axis did not reveal any other lesions.
A CSF flow study on MRI was also performed to look at CSF flow dynamics, and evaluate for possible CSF outflow obstruction secondary to this lesion, which might have explained the patient’s
headaches. Unobstructed CSF flow was identified anterior and posterior to the cervicomedullary
junction at the foramen magnum and at the level of the intramedullary lesion at C1-C2.
How would you treat this lesion?
A. Observation and close neurological follow up
B. Perform a lumbar puncture for CSF cytology
C. Radiation and/or chemotherapy

Figure 2

D. Excisional biopsy

Pre-op sagittal T1-weighted MRI

E. Excisional biopsy followed by radiation and/or chemotherapy
This is a young, otherwise healthy male who is starting to develop neurological symptoms from
a lesion with unknown pathology. Considering the rapid progression of his symptoms over a few
weeks, we felt that it was necessary to expediently secure him a diagnosis via direct exploration of the
lesion. Once the diagnosis was established, treatment tailored to his particular ailment could begin.
While operative exploration of this lesion entails risk of significant morbidity, we felt the severity of
his clinical findings and the progression of his deficit merited operative exploration.
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The diagnostic yield from CSF cytology is
low (~26%)(3), although repeated sampling
does increase the yield significantly. CSF flow
cytometry also increases the diagnostic yield
over CSF cytomorphology alone. (1) Newer
techniques like fluorescence in situ hybridization (FISH) enhance the diagnostic yield for
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the detection of malignancy on the first lumbar
puncture in patients clinically suspected of
having leptomeningeal metastases (LMM). (10)
Radiographic imaging did not demonstrate any
leptomeningeal spread in our patient. In the
absence of leptomeningeal spread, the chances
of obtaining a diagnosis from CSF cytology are
further diminished.

Figure 3

Figure 4

Pre-op sagittal T2-weighted MRI

Pre-op sagittal post-gadolinium MRI

Figure 5

Figure 6

Intraoperative ultrasound image, pre
resection

Intraoperative ultrasound image, post
resection

We decided to proceed with exploration and
biopsy of the tumor. We planned to debulk the
tumor and to possibly resect the entirety of the
tumor predicated upon the lesion’s histopathological findings at the time of frozen section and
intraoperative behavior. Debulking the tumor
would also alleviate the mass effect on the spinal
cord, decrease tumor burden, and afford the
patient a better chance at tumor control through
adjuvant chemotherapy and radiation.
How would you counsel the patient regarding
the surgical risks?
The risks and benefits of surgery were explained
at length. It was emphasized to the patient that
there was a substantial risk of neurologic worsening and a significant risk of paralysis secondary to the size of the tumor and its extremely
sensitive location. The patient had previously
suffered a significant head injury; hence, these
discussions were also carried out with patient’s
mother who acted as his guardian. While the
patient was felt to be thoroughly consentable,
the patient’s family was again counseled as to
the severity of his diagnosis and the significant
dangers of surgery.
What surgical approach would you
use? What intra-operative tools would
help you in localization of this lesion?
We decided to approach this lesion through a
posterior cervical approach. The patient was
positioned prone using the Mayfield three-pin
headholder. The patient’s neck was placed
in gentle flexion to facilitate exposure of the
occipitocervical junction. The posterior arch of
C1, along with 50% of the top of the lamina of
C2 was removed. At the base of the occiput, we
performed a limited suboccipital craniectomy
using the Midas-Rex drill.
The dura was opened next. Using intraoperative ultrasound localization, we identified the
patient’s large intramedullary tumor. We
attempted to map the spinal cords’ midline
using SSEPs; however, due to poor recordings
and extensive lateral spread, we were unable to
adequately map the posterior elements.

Figure 7

Figure 8

Post-operative sagittal CT

Post-operative sagittal MRI
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We chose an entry point along the posterior
elements. The spinal cord was entered via
bipolar and creating a sharp incision in the
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hemisphere gangliogliomas. Histological grade
was not predictive of outcome, although in each
location there was a trend for higher-grade
tumors to have a shorter time to recurrence.(6)
It is concluded that radical surgery leads to longterm survival of patients with gangliogliomas,
regardless of location, and adjuvant therapy
can probably be reserved for special cases (e.g.
tumors with a high KI 67 index). (4, 5, 7-9)
References

Figure 9

Figure 10

Atypical ganglion cells including binucleated ganglion cell

Chromogranin staining of atypical ganglion
cells in background of neoplastic glial cells

pia mater. The cord was opened further using
microscissors. Using blunt dissection, we gently
reflected the pia-arachnoid. Using pial sutures,
we gently retracted the spinal cord bilaterally.
The patient’s intramedullary tumor was evident.
Using blunt dissection, we gently developed
a plane around the patient’s intramedullary
tumor. A biopsy was obtained and sent for
frozen section. Frozen section returned a lowgrade astrocytoma.
We continued our resection, removing as much
of the tumor as we felt safe. We periodically
checked motor evoked potentials during our
decompression. After we had completed our
decompression, we used the ultrasound to
confirm that no further gross elements of
tumor were evident. There was a gliotic shell,
which was evident around the spinal cord;
however, based on ultrasound localization, the
main portion of the patient’s tumor had been
successfully extirpated.
There was some mild loss of hand intrinsic
motor evoked potentials during the procedure;
however, this was less than 50% loss and was
not felt to be severe. After hemostasis had been
achieved, the wound was thoroughly irrigated.
The dura was closed using #6-0 Gore-Tex
sutures.
Postoperatively, the patient recovered well. His
motor and sensory exam remained stable.
Permanent section was consistent with that of
ganglioglioma.
Ganglioglioma was first described by Courville in
1930 as a central nervous system neoplasm containing both astrocytic and neuronal components.
Gangliogliomas are firm grayish tumors that
may have cystic components. On light microscopy, atypical dysplastic neurons, astrocytes, and
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fibrovascular stroma are observed. Infrequently,
anaplastic degeneration occurs and involves
the astrocytic component. Neoplastic ganglion
cells are large and mature and reveal intense
immunoreactivity with synaptophysin, show
expression of the stem cell epitope CD34, and
are often binucleated.
Most gangliogliomas are observed in the brain.
Temporal lobes and cerebellar hemispheres are
the most common locations. Rarely, they may
also develop in the spinal cord. Only 1% of
intramedullary spinal neoplasms are histologically gangliogliomas.
Now that diagnosis has been established,
would you recommend any further treatment
for this patient?
Radical surgery for intraspinal tumors can
achieve long tumor-free survival without
requiring adjuvant therapy.(4) In cases of lowgrade tumor, radical excision is associated with
minimal morbidity and an excellent long-term
prognosis when carried out before significant
disability occurs.(2) Gangliogliomas are generally classified as WHO grade 1 lesions; however,
malignant transformation can occur.
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In one study, the 5-year actuarial survival
rates for cerebral hemisphere, spinal cord, and
brain-stem gangliogliomas were 93%, 84%,
and 73%, respectively (p = 0.7). The event-free
survival rate at 5 years was 95% for cerebral
hemisphere gangliogliomas and 36% for spinal
cord gangliogliomas (p < 0.05); for brain-stem
gangliogliomas the event-free survival rate at 3
years was 53% (p < 0.05). Multivariate analysis
(Cox linear regression) revealed tumor location
to be the only variable predictive of outcome,
with spinal cord and brain-stem gangliogliomas
having a 3.5- and 5-fold increased relative risk of
recurrence, respectively, compared to cerebral
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Intramedullary Spinal Cord Metastases
and Radiation Therapy: A Case Report
Daniel Ikeda, James S. Harrop MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

Introduction
Intramedullary spinal cord metastases (ISCM) are a clinically rare, although devastating, complication
of disseminated cancer. These lesions have been reported to originate from many types of solid
tumors, although primary lung carcinoma, particularly small cell, is the most common etiology.
These metastases, which can occur anywhere along the spinal cord, often represent the end-stage of
the disease process with limited survival outcomes.
Patients with ISCM may develop a variety of neurological deficits with treatment goals aimed at
palliation. Different modalities of treatment have been found to preserve or restore ambulation and
neurological function. The options for therapeutic intervention include surgical, chemotherapeutic,
and radiation therapy. We describe a case of ISCM in a patient with disseminated small cell lung
cancer with magnetic resonance imaging that illustrates a complete tumor response to radiation
therapy

Case Report

Figure 1A
Cervical MRI, prior to 30 Gy radiotherapy

In December of 2006, a 63 year-old male presented with extensive stage small cell lung carcinoma.
Upon initial presentation, this patient had a very large, left pulmonary mass, mediastinal lymphadenopathy, multiple hepatic lesions, and several osseous lesions. Due to the extent of his disease,
the patient was referred to medical oncology and treated with chemotherapy. A PET scan on July of
2007 revealed radiographic resolution of his malignancy following his chemotherapy. On October
3rd of 2007, after presenting with dizziness, it was found he had metastasis to his cerebellar vermis.
These metastases were treated with 30 Gy of whole brain radiation therapy and his vertigo significantly improved. A follow-up brain MRI showed a complete response to treatment with no residual
metastases found.
In December of 2007, the patient presented with bilateral shoulder and neck pain. The pain started
in his right shoulder radiating to his mid neck and then to his left shoulder. The pain had been
intermittent, but intense, over the previous few weeks and progressed to right arm numbness. There
was no associated muscle weakness in his upper or lower extremities bilaterally. The patient displayed
some mild right hand intrinsic weakness; deep tendon reflexes were found to be slightly increased
in his lower extremities versus his upper extremities. An open MRI with and without IV contrast
of the cervical spine was performed. A contrast enhancing mass within the cervical spinal cord was
noted and reported as an ependymoma, due to the infrequency of intraparenchymal metastasis. To
get better definition of the lesion, a repeat closed high-resolution MRI of the cervical, thoracic, and
lumbar spine was performed. The cervical contrast enhancing lesion was found to be three separate
intramedullary multifocal with measured total length of 4.5 cm (Figure 1A). There were no other
lesions in the spinal cord. The presence of three distinct lesions in the setting of metastatic disease was
consistent with multiple intraparenchymal metastatic disease rather than a primary intramedullary
neoplasm (ependymoma).
The patient’s disease was in remission and 30 Gy of cervical spine radiation was administered. The
patient reported that his symptoms of pain and numbness resolved completely with the radiation
therapy.
A follow-up MRI demonstrated a complete response and no evidence of the ISCM lesion (Figure 1B).

Discussion
Although rarely reported, ISCM have been found in 0.9% to 2.1% of cancer patients by autopsy,
suggesting that thousands of patients are afflicted yearly1. Primary lung carcinoma is the most common etiology and reported to occur in up to fifty percent of cases of ISCM2. In one retrospective
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Figure 1B
Cervical MRI, post radiotherap

study, small cell lung cancer was the most common primary tumor in patients with ISCM,
accounting for 63% of patients with primary
lung cancer and 30% of all patients studied2.
However, other solid tumors, including breast,
kidney, colorectal, cervical, and ovarian cancers
have also been reported3,4,5.
A variety of neurological disorders characterizes the presenting symptoms of ISCM
clinically. Schiff and O’Neill reported sensory
alteration (42.5%), pain (30%), and weakness
(30%) as the most common initial symptoms2.
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The symptoms of gait unsteadiness, urinary
incontinence, and Brown-Sequard syndrome
have also been described2,6.
Diagnosis of ISCM usually requires magnetic
resonance imaging (MRI) or computerized
tomography (CT), because plane films and
myelography are normal in 75% and 58% of
cases7. In addition, cerebral spinal fluid (CSF)
analysis is often non-diagnostic with the
most common abnormal finding of elevated
protein in only 20% of cases8. Computerize
tomography scanning has been found to be
diagnostic in few patients, which is demonstrated by increased density in the area of the
ISCM lesions. However, magnetic resonance
imaging (MRI) has greater sensitivity and
specificity7. MRI T2-weighted images show
alterations in signal intensity based on tissue
type and demonstrate accurate differentiation
between normal tissue of the spinal cord and
tumor  7. Gadolinium is a helpful adjunct to the
T2-weighted imaging as it reveals the enhancing
central lesion in typical ISCM7. In a study of 30
patients, there was only one false-negative MRI
study, and 23 of 25 patients receiving gadolinium
demonstrated contrast enhancement of ISCM
lesions on MRI2.
Treatment is generally palliative, as the median
survival ranges from 3.9 to 5 months2,9,10. Schiff
and O’Neill found that patients with breast
cancer as their primary tumor had the greatest
median survival, which still was only 13 months.
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Patients with other primary cancers including
lung carcinoma had a median survival of 3
months. As with our patient, surgery is often
contraindicated at the time of presentation,
making the less invasive modalities of chemotherapy and radiation therapy the mainstays
of treatment2,5,11. Radiation therapy has been
shown to improve or prevent deterioration
of neurological status. In Conill et al., they
reported improvement of neurological symptoms in 83% of patients with a mean duration
of 17.2 days. And Schiff and O’Neill reported
preservation of ambulation in 91% of patients
at their latest follow-up.
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Research

Department of Neurosurgery
Clinical Research Ongoing Studies
• Survey on Whether Patients Will Participate in a Blood
Transfusion Trial after Subarachnoid Hemorrhage
• Retrospective, Multi-Center Chart Review of the Wingspan™
Stent System with Gateway™ PTA Balloon System.
• Outcome of Patients with Ruptured Aneurysm Who
Underwent Endovascular Coiling Procedure and Evacuation
of Intracerebral Clot
• Micrus® Cerecyte™ Registry: a Registry to Evaluate Outcomes
at One Year Post-Embolization with the Micrus® Cerecyte™
• A Randomized, Clinical Trial of Unruptured Brain
Arteriovenous Malformations (ARUBA)
• Carotid Revascularization Endarterectomy vs. Stent Trial
(CREST)
• Surgical Anastomosis of the Superficial Temporal Artery to
the Middle Cerebral Artery (STA-MCA) when Added to the
Best Medical Therapy for Carotid Occlusion (COSS)
• Assessment of Intracranial Aneurysm Shape as an Indicator
of Rupture Risk
• Retrospective 5 Year Review of Follow-Up Angiogram on
Patients with Cerebral Aneurysms Post Clipping
• Retrospective Review of Post Treatment Hemorrhage Rates of
Patients with Arteriovenous Malformations (AVM’s)
• Role of Increased CSF Production in Clinical and Radiologic
Vasospasm

• Multicenter Retrospective Study of the Effectiveness,
Safety and Treatment Characteristics of Subcutaneous
Neurostimulation (SQS) in Patients with Chronic Pain
• Retrospective Review of Surgical Complications of Occipital
Nerve Stimulator Systems.
• Comprehensive Retrospective Review of Anterior Corpus
Callosotomy Outcomes at TJUH
• Incidence and Outcome of Patients with Spinal Fracture and
Ankylosing Spondylitis
• Magnetic Resonance Analysis of Postsurgical Temporal
Lobectomy and Correlation to Seizure Outcome
• Study of Seizure Outcomes in Patients Status Post Temporal
Lobectomy with Secondarily Generalized Seizures Comparing
Patients with and without Intracranial Implants
• Use of Discarded Tissue from Frontal and Temporal
Lobectomy
• Pilot Study Comparing Various Electrode and Program
Settings Using the EON IPG
• Prospective, Multi-Center, Randomized Controlled Study to
Compare the Spinal Sealant System As An Adjunct to Sutured
Dural Repair with Standard of Care Methods During Spinal
Surgery
• Changing Impedances over Time with Spinal Cord
Stimulation Systems

• Retrospective and Prospective Review of Peri-Operative
Complications in Patients Undergoing Spine Surgery

• Comparison of Preoperative ISAP (Intracarotid Sodium
Amobarbital Procedure-WADA Test) Results and PostOperative Outcomes in Patients Undergoing Temporal Lobe
Resection for Epilepsy.

• Assessing Patient Perspectives of Perioperative Complications
in Spinal Surgery

• Comparison of Placement of Spinal Cord Stimulators in the
Awake Vs. Non Awake Patient

• Retrospective Chart Review: the Use of Pre-Operative and
Intra-Operative Ultrasound in the Evaluation of Peripheral
Nerve Disorders

• Pilot Study for the Evaluation of Tripole Electrodes in Spinal
Cord Stimulation
• Epilepsy Surgery Complications Relative to Age
• Occipital Cervical Injury Outcomes
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• Magnetic Resonance Imaging of Spinal Cord Injury:
Correlation with Clinical Findings and Outcome
• Use of Expandable Vs. Non-Expandable Cages in Vertebral
Body Replacement Surgery: a Retrospective Review of
Outcomes at Jefferson
• Neurological Deterioration After Spinal Cord Injury.
• Radiographic Evaluation of Intersegmental Correction
of Cervical Kyphosis with Combined Anterior Interbody
Grafting and Posterior Instrumented Arthrodesis
• Magnetic Resonance Imaging of Cervical Spondolytic
Myelopathy: Correlation between Findings and Outcome.
• Retrospective Review of the Correlation between Increased
T2 Weighted Signal on Cervical Spine MRI to Myelopathic
Clinical Signs

• Prospective, Multicenter, Randomize, Study Comparing the
Use of HEALOS to Autograft in a Transforminal Lumbar
Interbody Fusion (TLIF) Approach
• Single Blind, Randomized Evaluation of Dilute Betadine
Solution Irrigation versus Normal Saline Irrigation in the
Prevention of Postoperative Posterior Wound Infection in
Posterior Instrumented Spinal Surgeries
• North American Clinical Trials Network (NACTN) for
Treatment of Spinal Cord Injury
• Flexicore Intervertebral Disc versus Circumferntial Lumbar
Spinal Fusion for the Treatment of Discogenic Pain
Unresponsive to Conservative Treatment Associated with
Degenerative Disc Disease
• Assessment of P-15 Bone Putty in Anterior Cervical Fusion
with Instrumentation Investigational Plan

• Retrospective Chart Review of Cases Done at Thomas
Jefferson University: the Failure Rate in Surgical Treatment
with Fixation of C1-C2 Fracture

• Multicenter Retrospective Chart Review Reviewing the
Safety and Efficacy of the Enterprise Stent in Patients with
Intracranial Aneurysm

• Retrospective Chart Review of TJUH Patients Who
Obtained Epidural Injections; Looking at the Post
Procedural Complications

• Cordis Enterprise™ Vascular Reconstruction Device (VRD)
and Delivery System (DS): a Humanitarian Use Device
(HUD)

• Atlanto-Occipital Dislocation (AOD) Injuries: A
Retrospective Review of Management and Outcome

• Humanitarian Use Device: Neuroform Microdelivery Stent

• Clinical Outcome in Closed Head Injury: a Retrospective
Review of Patients That Received Transfusion (FFP) versus
Patients Who Were Not Transfused
• A Research Study of the Surgical Techniques and Clinical
Outcome for Interarticularis Pars Repair of the Lumbar
Spine
• Clinical Evaluation and Incidence of C 5 Palsy after Cervical
Spine Surgery
• Retrospective Review of the Multicenter Spinal Cord Injury
Database Utilized for the Pharmacologic Trial Sygen:
Defining the Incidence of Neurological Variability after
Complete Thoracic ASIA A Spinal Cord Injuries
• Prospective Database of Primary Spinal Neoplasms
• Phase I/II Dose-Ranging Study to Evaluate the Safety,
Tolerability, and Pharmacokinetics of BA-210 and the
Neurological Status of Patients after a Single, Extradural
Application of Cethrin (BA-210) during Surgery for Acute
Thoracic and Cervical Spinal Cord Injury (SCI)
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• The Wingspan™ Stent System and Gateway™ PTA Balloon
Catheter, a Humanitarian Use Device
• Stenting and Aggressive Medical Management for
Preventing Recurrent Stroke in Intracranial Stenosis
(SAMMPRIS)
• Pilot Research Study of Coumadin versus Plavix for the
Treatment of Phase III, Randomized, Parallel Group,
Multi-Centre Study in Recurrent Glioblastoma Patients
to Compare the Efficacy of Cediranib [RECENTIN™,
AZD2171] Monotherapy and the Combination of Cediranib
with Lomustine to the Efficacy of Lomustine Alone
• Use of Fractionated Stereotactic Radiotherapy for the
Treatment of Optic Nerve Sheath Meningiomas: a
Retrospective Medical Record Review
• Retrospective Chart Review of Fractionated Stereotactic
Radiotherapy for the Treatment of Residual
Craniopharyngioma
• In Vitro Pilot Study to Determine the Capacity of Glioma
Cells and Metastatic Intracranial Tumor Cells to CrossPrime Dendritic Cells and Induce a Measurable Anti-Tumor
Cytotoxic T Cell Response
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• Prospective National Study to Molecularly and Genetically
Characterize Human Gliomas: the Glioma Molecular
Diagnostic Initiative (GMDI)
• Prospective Glioma Patients Archival Database Including
Parallel Clinical, Radiographic, Histopathological, and
Unsupervised Microarray Analyses
• Exploratory Phase 2 Study Evaluating the Efficacy and Safety
of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated
(FS VH S/D) 500 S-APR for the Sealing of Dura Defect
Sutures in Posterior Fossa Surgery
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• Surgical Treatment of Pituitary Tumor-Transition From
Open to Endoscopic Approach
• Overall Experience of Pituitary Tumor Patients at Thomas
Jefferson University
• Growth of the Cranial Base Program-Otolaryngology/
Neurosurgery Experience

30

Rosenwasser MD: JHN

Neurosurgery
Grand Rounds
Overall Goals & Objectives
• Evaluate current controversies in neurosurgery
• Discuss routine occurrences in neurosurgical practice and evaluate
them in terms of outcome and alternative methods of management
• Review recent advances and current therapeutic options in the
treatment of various neurosurgical disorders.
Jefferson Medical College of Thomas Jefferson University is accredited by the ACCME to
provide continuing medical education for physicians.

Fridays, 7:00 am
De Palma Auditorium
1025 Walnut Street
College Building, Basement
Philadelphia, PA 19107

Jefferson Medical College designates this educational activity for a maximum of 1 AMA
PRA Category 1 Credit(s)(TM). Physicians should only claim credit commensurate with
the extent of their participation in the activity.
For additional information and a schedule of speakers, please contact:
Janice Longo
215-503-7008
janice.longo@jefferson.edu

8th Annual
Cerebrovascular Update 2009

Current Concepts for
Stroke Management
and Prevention
March 19-20, 2009
Park Hyatt at the Bellevue,
Philadelphia, PA
Course Directors
Rodney D. Bell, MD
Professor of Neurology
Chief, Division of Cerebrovascular Disease
and Neurological Critical Care

Robert H. Rosenwasser, MD, FACS
Professor and Chairman of Neurological
Surgery
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